Statin Safety and Drug Interactions: Clinical Implications

This publication has 32 references indexed in Scilit:

• Rosuvastatin: A High-Potency HMG-CoA Reductase Inhibitor
  Journal of the American Pharmacists Association, 2005
• Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs
  JAMA, 2004
• Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
  New England Journal of Medicine, 2004
• Effect of Intensive Compared With Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis
  JAMA, 2004
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
  Circulation, 2002
• ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins
  Stroke, 2002
• Cerivastatin and Reports of Fatal Rhabdomyolysis
  New England Journal of Medicine, 2002
• A general assessment of the safety of HMG CoA reductase inhibitors (statins).
  Current Atherosclerosis Reports, 2002
• Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
  JAMA, 1998
• Comparative Dose Efficacy Study of Atorvastatin Versus Simvastatin, Pravastatin, Lovastatin, and Fluvastatin in Patients With Hypercholesterolemia (The CURVES Study) fn1fn1This study was supported by Parke-Davis, Division of Warner Lambert Company, Morris Plains, New Jersey. Manuscript received August 20, 1997; revised manuscript received and accepted November 24, 1997.
  The American Journal of Cardiology, 1998